Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7048360 | 0.92 | HTT (0.45) | LMNAMAPTSMN1; SMN2TSHRHTT | |
| SCHEMBL7043453 | 0.90 | LMNA (0.43) | LMNAMAPTSMN1; SMN2TSHRHTT | |
| SCHEMBL6466282 | 0.87 | LMNA (0.39) | LMNAMAPTSMN1; SMN2TSHRHTT | |
| SCHEMBL7045974 | 0.86 | CTSS (0.43) | LMNAMAPTSMN1; SMN2TSHRHTT | |
| SCHEMBL7047935 | 0.84 | LMNA (0.37) | LMNAMAPTSMN1; SMN2TSHRHTT | |
| SCHEMBL7049029 | 0.82 | RAB9A (0.38) | LMNAMAPTSMN1; SMN2TSHRKMT2A | |
| SCHEMBL7046906 | 0.76 | MAPT (0.43) | LMNAMAPTSMN1; SMN2TSHRHTT | |
| SCHEMBL6464160 | 0.76 | LMNA (0.39) | LMNAMAPTSMN1; SMN2TSHRHTT | |
| SCHEMBL7045443 | 0.74 | MEN1 (0.45) | LMNAMAPTSMN1; SMN2TSHRKMT2A | |
| SCHEMBL7044868 | 0.73 | LMNA (0.37) | LMNAMAPTSMN1; SMN2TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1516877-A1 | Amine derivatives as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | LMNA 1755/4885MAPT 2414/4885SMN1; SMN2 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.